Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Nuocheng Jianhua (09969.HK) will hold a board meeting on May 13 to approve the first quarter results
Glonghui, April 29, 丨 Nuochengjianhua (09969.HK) announced that the company will hold a board meeting on May 13, 2024 to consider and approve the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Capital from the south will cross the Hong Kong River again! What is the “success” of the individual stocks listed in AH and AH?
① Among AH listed companies, the target with the highest premium rate reached 6 times; ② the individual stocks with the most significant performance improvement in 2023 among AH listed companies came from the power equipment industry; ③ H shares in AH listed companies account for relatively high targets mainly central state-owned enterprises.
Nuocheng Jianhua (688428): Hematoma first-mover advantage stabilizes the self-immunity pipeline and the harvest period is approaching
Nuochengjianhua (688428.SH) is a commercial-stage biomedical company. Since its establishment in 2015, 2 hematoma products have been approved for sale, and 13 products are in the clinical stage, covering hematomas, immune diseases, and
InnoCare Pharma Limited Expects Multiple Drug Products to Reach Approval
諾誠健華:二零二三年年報
The Singapore Government Investment Corporation sold 21.417,200 common shares of Nuochengjianhua (09969.HK), worth approximately HK$106 million
On April 17, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 17, the Singapore Government Investment Corporation (GIC (Ventures) Pte. Ltd.) sold $21.417,200 common shares worth approximately HK$106 million at an average price of HK$4.9583 per share on April 11. After the sale, the latest number of shares held by the Singapore Government Investment Corporation was 87.998 million shares, and the good position ratio dropped from 6.21% to 4.99%. This transaction involves other related parties: GIC Private L
King Bridge Investments Limited sold 310,000 shares of Nuochengjianhua (09969.HK) common shares worth approximately HK$1,520,900
On April 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 12, King Bridge Investments Limited sold $310,000 common shares worth HK$1,520,900 at an average price of HK$4.9062 per share on April 12. After the sale, King Bridge Investments Limited's latest shareholding was 106 million shares, and the good position ratio dropped from 6.01% to 5.99%. Photo Source: Stock Exchange Shareholding Disclosure
Nuocheng Jianhua (9969.HK): Many products whose performance is in line with expectations will soon be submitted for NDA
Introduction to this report: Obutinib's revenue in 2023 was 671 million yuan (+18.5%). Clinical progress for hematomas, immunization, and solid tumors is progressing smoothly. Various drugs are expected to be submitted to the NDA in 2024. We are optimistic about the company's future development and maintenance
Looking for new pharmaceutical productivity: Looking at the high-quality development of local innovative pharmaceutical companies from Nuochengjianhua (9969.HK/688428.SH)
“New quality productivity” is becoming one of the most popular terms recently. In March 2024, the report on the work of the Chinese government identified “developing new quality productivity” as the top priority at present. Among them, innovative drugs are clearly mentioned for the first time in the “Actively Cultivating Emerging Industries and Future Industries” section, stating that it is necessary to “accelerate the development of the cutting-edge and emerging innovative drug industry, actively build a new growth engine for biomantry manufacturing, open up a new life science circuit, and create a number of pioneering zones for future industries” to add another spring breeze to the innovative drug circuit. Well, in an age where the innovative drug industry is receiving so much attention from top-level design, it
Read Nuochengjianhua's 2023 performance report in one picture
On March 28, Nuochengjianhua announced its 2023 performance report. The following will take you to read Nuochengjianhua's 2023 performance report with a picture.
Press Release: InnoCare Releases 2023 Results and Business Highlights
InnoCare Releases 2023 Results and Business Highlights BEIJING--(BUSINESS WIRE)--March 28, 2024-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer a
INNOCARE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Nuochengjianhua (688428.SH) announces 2023 annual results, core product sales growth, net loss narrows to 631 million yuan
Nuochengjianhua (688428.SH) disclosed its 2023 annual report. The company achieved operating income of 7 during the reporting period...
Nuocheng Jianhua (688428): Starting with innovation, strong execution, the pipeline in the field of hematoma and self-immunity has blossomed
Ping An View: Based on R&D and innovation, obutinib has blossomed in the fields of hematoma and self-immunity. The company's founding management team is experienced in the industry, has an international innovation vision, and understands the pain points and needs of the industry. Currently, two products have been commercialized, including obutinib
Highbury Investment Pte Ltd sold 1.173,000 common shares of Nuochengjianhua (09969.HK), worth approximately HK$5.832 million
On March 18, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 18, Highbury Investment Pte Ltd sold $1.173,000 common shares at an average price of HK$4.9703 per share on March 12, worth approximately HK$5.832 million. After the sale, Highbury Investment Pte Ltd's latest shareholding was 87.275 million shares, and the good position ratio dropped from 5.02% to 4.95%. Additional Information: Cautious to h
Nuocheng Jianhua (09969.HK) held a board meeting on March 28 to consider and approve the annual results
Glonghui March 15 | Nuochengjianhua (09969.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
INNOCARE: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Nuochengjianhua (09969) has now risen more than 4%, and the BCL2 inhibitor ICP-248 combined with obutinib has been clinically approved for treatment of CLL/SLL
Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.51% to HK$5.33, with a turnover of HK$396.03 million.
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
No Data